Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antifibrotic agents for liver disease.

E Albanis1, S L Friedman

  • 1Division of Liver Diseases, Mount Sinai Medical Center, New York, New York, USA. efsevia.albanis@msnyuhealth.org

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|January 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis.

Journal of hepatology·2025
Same author

Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis.

Alimentary pharmacology & therapeutics·2016
Same author

Early Liver Transplantation for Severe Alcoholic Hepatitis in the United States--A Single-Center Experience.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Standard operating procedures in experimental liver research: thioacetamide model in mice and rats.

Laboratory animals·2015
Same author

GSK3β phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21.

Oncogene·2012
Same author

Natural history of small duct primary sclerosing cholangitis: a case series with review of the literature.

Hepatology international·2011

New antifibrotic therapies show promise for treating chronic hepatitis C (HCV) complications and recurrence after liver transplantation. These novel approaches target hepatic fibrosis, aiming to reduce cirrhosis, mortality, and re-transplantation needs.

Area of Science:

  • Hepatology
  • Fibrosis research
  • Transplantation medicine

Background:

  • Chronic hepatitis C (HCV) and post-transplant recurrence cause significant morbidity and mortality.
  • Current antiviral therapies for HCV have limited efficacy (≤50%) and increased toxicity, especially post-transplant.
  • There is an urgent need for novel therapeutic strategies.

Purpose of the Study:

  • To review the progress and potential of antifibrotic therapies for managing hepatic fibrosis.
  • To highlight new therapeutic targets in fibrogenesis, particularly activated hepatic stellate cells.
  • To discuss the future directions and challenges in antifibrotic treatment for HCV.

Main Methods:

  • Review of recent advancements in understanding hepatic fibrosis pathogenesis.

Related Experiment Videos

  • Analysis of current and emerging antifibrotic therapeutic targets.
  • Discussion of clinical trial considerations and future research needs.

    • Main Results:

    • Significant progress in understanding fibrosis has identified potential new therapeutic targets.
    • Antifibrotic therapies targeting activated hepatic stellate cells are nearing clinical reality.
    • These therapies aim to reduce fibrosis progression, cirrhosis, and the need for re-transplantation.

    Conclusions:

    • Antifibrotic therapies offer a promising new avenue to combat HCV-related complications and post-transplant recurrence.
    • Further research is needed to clarify optimal treatment duration, clinical trial endpoints, and combination therapy strategies.
    • Successful implementation of antifibrotics could significantly improve patient outcomes and reduce healthcare burdens.